5 results about "Nicotine replacements" patented technology

The invention discloses a composite probiotic preparation capable of improving sensitivity of low-dose nicotine and reducing usage amount of nicotine, and belongs to the crossing field of microbial technology and biological medicine. The compound probiotic preparation only improves the sensitivity of mice to low-concentration nicotine, does not improve the preference of the mice to the existing preference concentration, prevents aggravated smoking addiction, enables individuals to reach the satisfaction of smoking at ordinary times under the condition of low dosage of nicotine, and has the advantages of being simple in preparation process, low in cost and the like. The formulations may be used in combination with products in nicotine replacement therapy or alone. The compound probiotic preparation disclosed by the invention can be used for preparing functional foods, health-care products and medicines capable of improving the sensitivity of the low-concentration nicotine, and has a very wide application prospect.

The invention discloses nicotine jelly and a preparation method thereof. The nicotine jelly comprises a nicotine source and a jelly substrate, wherein the nicotine source is dispersed in the jelly substrate; wherein the nicotine source comprises a non-embedded nicotine source and a nicotine source embedded in the microcapsule particles. The nicotine jelly can adapt to different release scenes by adjusting the embedding proportion, safety and portability are both considered, and an innovative solution is provided for nicotine replacement therapy.

This application belongs to the field of food or pharmaceutical technology, specifically relating to a lozenge and its preparation method. The lozenge includes a granular composition comprising the following components: an active substance, a cationic resin, cationic salt sustained-release granules, and a filler; wherein the active substance includes at least one of the following: nicotine or a nicotine derivative. This solution incorporates cationic salt sustained-release granules into the lozenge, which not only effectively prevents the rapid dissolution of the cationic salt, allowing it to maintain an effective concentration in the oral cavity for a prolonged period, thus facilitating sufficient contact with the cationic resin to ensure nicotine replacement, but also regulates the release rate of the cationic salt, thereby regulating the nicotine replacement rate.

The present disclosure relates to methods incorporating the use of a biomarker (CEVal) for assessing compliance with a smoking cessation program, for example, a smoking cessation program which involves subjects switching from conventional cigarettes to a hybrid device, an e-cigarette and / or a tobacco heating product, a smoking cessation program involving the use of nicotine replacement therapy, a smoking cessation program involving lifestyle choices or therapy, or a combination thereof.

A device for providing nicotine replacement therapy may be provided. The device may comprise a processor. The processor may be configured to perform one or more actions. A cessation program for a user may be determined. A program intervention event based on a phase of the cessation program may be determined. A marker associated with the user may be determined. A modification to the cessation program may be determined based on the program intervention event.